Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Multiple Myeloma is a type of blood cancer. In this study, we are testing a medicine called belantamab mafodotin, which targets a specific protein on cancer cells, called BCMA. It’s like a special medicine that attaches to cancer cells to help destroy them. This study is for adults who have had multiple treatments for their cancer but still need help. Participants will receive belantamab mafodotin alone or with other anti-cancer medicines.

• Participants must be 18 years or older and have had at least three previous cancer treatments.
• People with certain medical conditions, like serious heart problems or infections, cannot join.
• The study involves multiple visits and checks to ensure safety.

Joining this study could help researchers find better ways to treat multiple myeloma, but there might be risks, such as side effects from the medicine. Participants will be closely monitored by doctors to manage any issues that arise during the study. 🧪